SH-1028

SH-1028 · Nanjing Sanhome Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for SH-1028, covering 2019-01-28 to 2023-10-12. Get the full timeline:

Most recent: Clinical Trial Update: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations [Phase 3]

See pricing